PRAM-1 activators are a category of chemical compounds designed to modulate the activity of the PRAM-1 protein, which is an acronym for a specific protein associated with various cellular signaling pathways. PRAM-1 plays a role in mediating intracellular communications and can influence a wide range of cellular processes, including signal transduction mechanisms that govern the function of cells. Activators of PRAM-1 are intended to enhance the protein's natural activity, generally by promoting its interaction with other signaling molecules or stabilizing the protein in an active state that facilitates its participation in signaling networks. The development of PRAM-1 activators requires detailed knowledge of the protein's structure and function. This includes understanding the domains that are involved in protein-protein interactions and the conformational states that are associated with its active form. Using a variety of biochemical and biophysical techniques, such as affinity binding assays and molecular dynamics simulations, researchers are able to identify and characterize the binding sites and structural motifs that are critical for PRAM-1's activity.
Once the key areas of the PRAM-1 protein have been identified, the design of activators can be approached through structure-activity relationship studies and rational drug design. These activators typically feature molecular frameworks that enable them to interact with PRAM-1 with high affinity and specificity. The interactions may include a range of non-covalent bonds, such as hydrogen bonds, electrostatic interactions, and hydrophobic contacts, which together facilitate a stable interaction with the protein. The specificity of these activators is paramount, as it ensures the selective modulation of PRAM-1 without unintended interactions with other proteins that could disrupt cellular homeostasis. The design process often involves iterative rounds of synthesis and testing, where the effects of various substituents on the parent compound are evaluated to optimize the activators' properties.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $96.00 $166.00 $459.00 $1615.00 | 12 | |
LPS may initiate a potent immune response by triggering Toll-like receptor 4 (TLR4), potentially leading to the upregulation of PRAM-1 as part of the innate immune response. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which can stimulate transcription factors such as NF-κB, potentially leading to an increase in PRAM-1 synthesis. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin can elevate intracellular cAMP levels, which may subsequently activate protein kinase A (PKA), potentially resulting in the enhanced transcription of PRAM-1. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone, through glucocorticoid receptor activation, may lead to the transcriptional activation of genes involved in anti-inflammatory pathways, including a possible upsurge in PRAM-1 expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine may induce hypomethylation of genomic DNA, which could lead to the unveiling of promoter regions and an increase in the transcription of PRAM-1. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, by inhibiting histone deacetylases, may lead to a more accessible chromatin state, potentially stimulating the transcription of genes like PRAM-1. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid can bind retinoic acid receptors (RARs) and retinoid X receptors (RXRs), potentially leading to the activation of signaling pathways that upregulate PRAM-1 expression. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $62.00 $178.00 | 8 | |
β-estradiol may bind to estrogen receptors and activate estrogen-responsive elements within the DNA, which could lead to a surge in PRAM-1 transcription. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium butyrate may inhibit histone deacetylation, leading to an open chromatin configuration and potentially stimulating the expression of genes like PRAM-1. | ||||||
Lipoxin A4 | 89663-86-5 | sc-201060 sc-201060A sc-201060B sc-201060C | 25 µg 50 µg 100 µg 250 µg | $342.00 $485.00 $923.00 $2025.00 | 2 | |
As a specialized pro-resolving mediator, Lipoxin A4 may activate cellular pathways that resolve inflammation, potentially prompting an upregulation of PRAM-1 expression. |